AbSci a global leader in biomanufacturing technologies, was granted a European regional patent today for its SoluPro™ protein production technology. “Many years of discovery went into developing the SoluPro™ expression platform. The SoluPro™ technology provides a revolutionary solution to one of biomanufacturing’s ongoing challenges …
AbSci’s manufacturing platform could speed drug discovery
“I wasn’t there when Bill Boeing did his seaplane or when Bill Gates was coming up with software programs. But I’m here,” Inslee told Sean McClain, founder and CEO of AbSci, on Monday.
AbSci announced today that the company has finalized a lease agreement to relocate its headquarters to the new Hudson Building in downtown Vancouver, WA. AbSci expects to begin renovations by the beginning of September, and plans to take occupancy of the state-of-the-art lab facility by Q4 of this year, where the company will continue to develop and commercialize its revolutionary protein production technology.